Motohiro Kato
- Hematology top 1%
- Acute Myeloid Leukemia Research 37
- Hematopoietic Stem Cell Transplantation 29
- Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism 32
- Neurology top 1%
- Neurological disorders and treatments 26
- Oncology top 2%
- Drug Transport and Resistance Mechanisms 33
-
- Neuroscience and Neuropharmacology Research 25
-
- Acute Lymphoblastic Leukemia research 52
-
- Childhood Cancer Survivors' Quality of Life 29
- Co-authors
- Shozo TobimatsuYuichi SugiyamaSeishi OgawaAtsushi ManabeMasashi SanadaJunko TakitaFumio ShimaMinoru Kimura
- Cited by
- HematologyPharmacologyNeurology
- Partner nations
- JapanUnited StatesGermany
In The Last Decade
Motohiro Kato
330 papers receiving 6.6k citations
Hit Papers
Peers
Comparison fields: 5 of 143
- Hematology 1.0k
- Pharmacology 752
- Neurology 1.3k
- Oncology 1.3k
- Cellular and Molecular Neuroscience 841
Countries citing papers authored by Motohiro Kato
This map shows the geographic impact of Motohiro Kato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Motohiro Kato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Motohiro Kato more than expected).
Fields of papers citing papers by Motohiro Kato
This network shows the impact of papers produced by Motohiro Kato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Motohiro Kato. The network helps show where Motohiro Kato may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Motohiro Kato, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 4 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 0 | |
| 7 | 2023 | 1 | |
| 8 | 2023 | 3 | |
| 9 | 2022 | 1 | |
| 10 | 2022 | 0 | |
| 11 | 2022 | 1 | |
| 12 | 2021 | 2 | |
| 13 | 2021 | 5 | |
| 14 | 2020 | 4 | |
| 15 | 2020 | 3 | |
| 16 | 2020 | 3 | |
| 17 | 2019 | 2 | |
| 18 | Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on | 2018 | 403 |
| 19 | 2010 | 71 | |
| 20 | 2009 | 52 |
About Motohiro Kato
Motohiro Kato is a scholar working on Hematology, Pharmacology and Neurology, having authored 354 papers that have together received 6.8k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (52 papers), Acute Myeloid Leukemia Research (37 papers), Drug Transport and Resistance Mechanisms (33 papers), Pharmacogenetics and Drug Metabolism (32 papers), Childhood Cancer Survivors' Quality of Life (29 papers), Hematopoietic Stem Cell Transplantation (29 papers), Neurological disorders and treatments (26 papers) and Neuroscience and Neuropharmacology Research (25 papers). The work is most often cited by research in Hematology (1.0k citations), Pharmacology (752 citations) and Neurology (1.3k citations). Motohiro Kato has collaborated with scholars based in Japan, United States and Germany. Frequent co-authors include Shozo Tobimatsu, Yuichi Sugiyama, Seishi Ogawa, Atsushi Manabe, Masashi Sanada, Junko Takita, Fumio Shima, Minoru Kimura, Shinichi Hosokawa and Yuyan Chen. Their work appears in journals such as Nature, Nature Communications and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.